TG slips out a nasty surprise for investors

TG Therapeutics has worked hard, sometimes against the odds, to convince investors and the FDA of the benefits of U2, its chronic lymphocytic leukaemia project. Yesterday the story took another twist as it emerged that the combo, under review by the agency for close to a year, was on partial clinical hold.